Darolutamide
Clinical data | |
---|---|
Trade names | Nubeqa |
Other names | Darramamide, ODM-201, BAY-1841788 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a619045 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth |
Drug class | Nonsteroidal antiandrogen |
ATC code | |
Legal status | |
Legal status | |
UGT1A1)[4] | |
Metabolites | Ketodarolutamide[4][7] |
Elimination half-life | 16–20 hours[4][7] |
Excretion | Urine: 63.4%[4] Feces: 32.4%[4] |
Identifiers | |
| |
JSmol) | |
| |
| |
(verify) |
Darolutamide, sold under the brand name Nubeqa, is an
Darolutamide was patented in 2011 [13] and was approved for medical use in USA in July 2019,[8][14] in the European Union in March 2020 [5] in Australia in July 2020.[15] and in Canada in 2020,
Medical uses
Darolutamide is approved for use concurrently with a
Two 2020 meta-analyses reported that enzalutamide and apalutamide seemed to be more effective than darolutamide in improving metastasis-free survival (MFS), however 2021 matched adjusted indirect comparison showed no significant differences between drugs in terms of MFS.[16][17][18] According to 2021 meta-analysis darolutamide was ranked first in terms of improving overall survival (OS).[19] Also, darolutamide showed significantly lower rate of grade 3-5 adverse events (AE) compared to both enzalutamide and apalutamide.[19]
Available forms
Darolutamide is provided in the form of 300 mg oral film-coated tablets.[4]
Contraindications
Darolutamide has no
Side effects
The most common
No
Overdose
Darolutamide has been studied at a dosage of up to 1,800 mg/day in clinical trials.
Interactions
Combined
Pharmacology
Pharmacodynamics
Darolutamide is a second- or third-generation
A dosage of darolutamide of 1,200 mg/day has been found to result in a mean decrease in
Darolutamide shows some advantages in comparison to enzalutamide and
Darolutamide inhibits the
Pharmacokinetics
Absorption
The
Distribution
The
Metabolism
Darolutamide is primarily
Excretion
After a single oral dose of darolutamide, more than 95% of the dose is excreted in urine and feces within one week following administration.[4] A total of 63.4% darolutamide-related material is recovered in urine (about 7% as unchanged darolutamide) and a total of 32.4% darolutamide-related material (about 30% as unchanged darolutamide) is recovered in feces.[4]
Variability
No clinically significant differences in the
Chemistry
Darolutamide is a nonsteroidal compound and is structurally distinct from other marketed NSAAs, including enzalutamide and apalutamide.[10]
History
Darolutamide was developed by
Approval was based on ARAMIS,[41] a multicenter, double-blind, placebo-controlled clinical trial in 1,509 patients with non-metastatic castration resistant prostate cancer. Patients were randomized (2:1) to receive either 600 mg darolutamide orally twice daily (n=955) or matching placebo (n=554). All patients received a gonadotropin-releasing hormone (GnRH) analog concurrently or had a previous bilateral orchiectomy. Twelve patients with previous seizure histories were treated on the darolutamide arm.[8][14]
The primary endpoint was metastasis free survival (MFS), defined as the time from randomization to first evidence of distant metastasis or death from any cause within 33 weeks after the last evaluable scan, whichever occurred first. The median MFS was 40.4 months (95% CI: 34.3, not reached) for patients treated with darolutamide compared with 18.4 months (95% CI: 15.5, 22.3) for those receiving placebo (hazard ratio 0.41; 95% CI: 0.34, 0.50; p<0.0001).
Darolutamide was associated with greater benefits than placebo for all secondary end points, including overall survival (hazard ratio 0.69; 95% CI: 0.53-0.88; P=0.003), time to pain progression (median 40.3 months vs. 25.4 months; hazard ratio 0.65; 95% CI: 0.53-0.79; P<0.001), time to cytotoxic chemotherapy (hazard ratio 0.43; 95% CI: 0.31-0.60), and time to a symptomatic skeletal event (hazard ratio 0.43; 95% CI: 0.22-0.84).[41]
Society and culture
Generic names
Darolutamide is the
andBrand names
Darolutamide is marketed under the brand name Nubeqa.[4][8][5]
Availability
Darolutamide is available in the United States and the European Union.[4][8][5][43]
Research
Darolutamide monotherapy is being studied in comparison to
Darolutamide is being studied for the treatment of breast cancer in women.[38] As of November 2019, it is in phase II clinical trials for this indication.[38]
References
- ^ "Nubeqa Australian prescription medicine decision summary". Therapeutic Goods Administration (TGA). 4 March 2020. Retrieved 16 August 2020.
- ^ "Product Monograph" (PDF). hres.ca. Retrieved 25 October 2023.
- ^ "Summary Basis of Decision (SBD) for Nubeqa". Health Canada. 23 October 2014. Retrieved 29 May 2022.
- ^ a b c d e f g h i j k l m n o p q r s t u v w x y z aa ab ac ad ae af ag ah ai aj ak al am an ao ap aq ar as at au av aw ax ay az ba bb bc bd be bf bg bh bi bj bk bl "Nubeqa- darolutamide tablet, film coated". DailyMed. 31 July 2019. Retrieved 22 November 2019.
- ^ a b c d e "Nubeqa EPAR". European Medicines Agency (EMA). 29 January 2020. Retrieved 16 August 2020.
- ^ "Nubeqa Product information". Union Register of medicinal products. Retrieved 3 March 2023.
- ^ PMID 24974051.
- ^ a b c d e f This article incorporates text from this source, which is in the public domain: "FDA approves darolutamide for non-metastatic castration-resistant prostate cancer". U.S. Food and Drug Administration (FDA) (Press release). 31 July 2019. Archived from the original on 23 November 2019. Retrieved 22 November 2019.
- ^ PMID 26313416.
- ^ PMID 26137992.
- ^ S2CID 20624649.
- ^ S2CID 19162538.
- ^ a b "Androgen receptor modulating compounds".
- ^ a b This article incorporates text from this source, which is in the public domain: "Drug Trials Snapshots: Nubeqa". U.S. Food and Drug Administration (FDA). 9 August 2019. Archived from the original on 23 November 2019. Retrieved 22 November 2019.
- ^ "AusPAR: Darolutamide". Therapeutic Goods Administration (TGA). 3 August 2020. Retrieved 22 September 2020.
- S2CID 215748376.
- PMID 32924096.
- PMID 33818140.
- ^ PMID 34054128.
- PMID 24658665.
- S2CID 8639102.
- ^ PMID 30197098.
- ^ PMID 38272747.
In the darolutamide arm, the median (range) value of testosterone was 413 (209.0–1183.0) ng/dl at baseline and increased by 43.3% (5.7–144.0%) to a median (range) of 595.0 (260.0–1500.0) ng/dl at week 24. In the GnRH arm, the median (range) value of testosterone was 333.0 (210.9–844.0) ng/dl at baseline and decreased by –96.0% (–99.6% to –80.8%) to a median (range) of 12.9 (1.2–52.8) ng/dl at week 24. Figure 3 shows the absolute change in testosterone values from baseline over time for the two arms. [...] The median testosterone level increased by 43.4% at 24 wk. In comparison, testosterone increased by 114.3% at week 25 with enzalutamide monotherapy in the phase II trial of enzalutamide. This difference and its potential consequences will need to be studied further.
- ISBN 978-1-4557-5972-9.
- PMID 9471040.
- ISBN 978-0-08-055347-4. Archivedfrom the original on 11 June 2016.
- S2CID 25200595.
- ISSN 0732-183X.
- ISSN 0732-183X.
- ^ Clinical trial number NCT05526248 for "A Study Called ARAMON to Learn to What Extent Does Study Treatment With Darolutamide Affects Testosterone Levels in Men With Prostate Cancer That Had Not Been Treated With Hormonal Therapy Compared to Treatment With Enzalutamide (ARAMON)" at ClinicalTrials.gov
- PMID 24857068.
- S2CID 87513637.
- S2CID 232159762.
- PMID 31571146.
- PMID 31571095.
- PMID 10837715.
- PMID 10706193.
- ^ a b c d "Darolutamide - Bayer HealthCare/Orion". Adis Insight. Springer Nature Switzerland AG.
- ISBN 978-1-936287-46-8.
- PMID 23355790.
- ^ a b Clinical trial number NCT02200614 for "Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Nonmetastatic Castration-resistant Prostate Cancer (ARAMIS)" at ClinicalTrials.gov
- ^ "Darolutamide". ChemIDplus. U.S. National Library of Medicine.
- ^ Chustecka Z (31 January 2020). "Darolutamide (Nubeqa) Gets OK in Europe for Prostate Cancer". MedScape.
- ^ ISSN 0732-183X.
- ^ "ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer". ClinicalTrials.gov. 23 November 2016. Retrieved 16 August 2020.
External links
- "Darolutamide". Drug Information Portal. U.S. National Library of Medicine.